Bimatoprost/brimonidine

Drug Profile

Bimatoprost/brimonidine

Alternative Names: Brimonidine/bimatoprost

Latest Information Update: 31 Jul 2015

Price : $50

At a glance

  • Originator Allergan
  • Class Amides; Antiglaucomas; Antihypertensives; Lipids; Prostaglandins; Quinoxalines; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Prostaglandin F2alpha receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Dec 2013 Allergan completed a phase II trial in Glaucoma and Ocular hypertension in USA (NCT01863953)
  • 30 Jun 2013 Phase-II clinical trials in Ocular hypertension in USA (Ophthalmic)
  • 30 Jun 2013 Phase-II clinical trials in Glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top